DDInter172 DDInter1127
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
Measles virus vaccine live attenuated {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Talazoparib
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Tositumomab
Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Tositumomab